

Claudia Habl / ÖBIG Health Economics

PPRI Conference 28 June 2007

PPRI Conference 28.6.07



Who is GÖG?

### **GÖG = Gesundheit Österreich GmbH –** Founded per Federal Law on 31 July 2007 with three business units

- ÖBIG (Bundesinstitut für Gesundheitswesen) Austrian Health Institute, <u>www.oebig.org</u> founded in 1973
- FGÖ (Fonds Gesundes Österreich) Fund for a Healthier Austria, <u>www.fgoe.org</u>, founded in end 1980ies
- BIQG (Bundesinstitut für Qualität im Gesundheitswesen)
  Institute für Quality in Health Care, <u>www.biqg.org</u>





Pharmaceutical Pricing and Reimbursement Information - PPRI

- o Background
- o Objectives
- o Project Outline
- o Participants
- o Deliverables / Results







### Background

- Need for knowledge and analysis of the pharmaceutical pricing and reimbursement systems as well as an exchange of information and experience between policymakers in the different countries
- Previous and ongoing work:
  - G10 process
  - Pharmaceutical Forum (Pricing – Relative Effectiveness – Patient Information)
  - WHO activities
  - GÖG/ÖBIG studies
  - EURO-MED-STAT
  - EuroPharm DB





### **Need for PPRI**

Several questions, e.g.:

- How are prices of pharmaceuticals regulated?
  - prices at manufacturer level,
  - margins for wholesale and pharmacies
  - reimbursable medicines / OTC products
- Which medicines are reimbursed?
  - fully/partly (reimbursement rates)
  - which criteria are taken into account?
  - who decides on reimbursement?
- How to guarantee access to innovative pharmaceuticals?
- > Are there pharmaco-economic guidelines?
- Are prices of other countries looked at?
- Are there pharmaceutical budgets?

# 

# → 27 different pharmaceutical pricing and reimbursement systems in the enlarged EU

PPRI Conference 28.6.07





### **PPRI Objectives**

- Strengthening the **networking** of the relevant national authorities and institutions in the field of pharmaceuticals in the Member States and Associated Countries
- o **Assessing** the Needs of EU and national administration and policymakers with regard to knowledge and information transfer on PPRI
- o Country reports on pharmaceutical pricing and reimbursement ("pharma profiles")
- o Developing indicators (benchmarks) for the comparative analysis
- o **Analysing** and **Benchmarking** pharmaceutical pricing and reimbursement in the enlarged Europe
- o **Dissemination** of the project results





### **PPRI offers**

- ✓ Vital network, cooperation, lessons learning
- ✓ With the contribution of the participants: "pharma profiles" (up-to-date information and data on pricing and reimbursement systems)
- ✓ Comparative analysis of pricing and reimbursement policies

### **PPRI does not offer**


- ✓ A database on registered medicines (no database building → EMEA, EuroPharm)
- ✓ A database on pharmaceutical prices (→ GÖG/ÖBIG PPI)
- ✓ Utilisation data ( $\rightarrow$  Euro-Med-Stat, EuroDurg)

✓ Pharmaco-vigilance issues ( $\rightarrow$  EMEA and national CA)





### **PPRI Project organisation**



PPRI Conference 28.6.07





### **PPRI** Participants

- Commissioners: Austrian Federal Ministry of Health.
  Family and Youth; European Commission DG Sanco
- ✓ **Project leaders**: GÖG/ÖBIG, WHO Euro
- Participants: BE, BL, CY, DE, DK, EE, EL, FI, FR, HU, IT, IR, LT, LU, LV, MT, SK, NL, PL, PT, SE, UK; NO, CA, AL, TR and some Third Party Payers
- European and International stakeholders:
  EMEA, DG Enterprise, OECD, WHO Observatory
- European pharmaceutical projects: Euro-Med-Stat, SOGETI, EASP





# **PPRI time table**

- Project start: May 2005
- 1. Coordination Meeting: 1/2 September 2005, Vienna
- **2. Coordination Meeting:** 27/28 April 2006, Copenhagen
- 3. Coordination Meeting: 9/10 October 2006, Warsaw
- 4. Coordination Meeting: 1/2 March 2007, Rome
- 5. Coordination Meeting: 28 June 2007, Vienna

PPRI Conference: 29 June, 2007

Final Report: 30 October 2007






### **PPRI Pharma Profiles**

- ✓ Written by participating countries, edited by GÖG/ÖBIG and WHO Euro
- $\checkmark$  in a pre-determined, identical structure by
- ✓ using a 50-page template / stylesheet developed by the PPRI group after a
- ✓ needs assement with over 100 stakeholders at a national level and 14 international organisations exploring the core points of interest
- → So far 19 Pharma profiles completed (14 final, 5 drafts) and 5 more in the pipeline











## **PPRI Indicators**

- Developed by a task-group consisting of DE, AT, HU, IT, WHO Euro, FR and Sogeti Indicator
   Project representative with input from many stakeholders
- ✓ List with 21 core indicators
- ✓ "Soft" ~ qualitative and "hard" indicators
- $\rightarrow$  Used for Comparative Analysis






# **PPRI Website**

- ✓ <u>http://ppri.oebig.at</u>
- $\checkmark$  Public site and intranet solution

# **PPRI Glossary**

# **Dissemination Activities**







### **Glossary Example**

Preferred Term: Pay-back

Synonym Term: Payback

### **Definition / Description:**

A cost-containment measure; a financial mechanism that requires manufacturers to refund a part of their revenue to a payer (e.g. social health insurance / national health service) if sales exceed a previously determined or agreed target budget

→ <u>http://ppri.oebig.at</u> → select glossary





# **PPRI** Report

- Contains a comparative analysis of all participating countries
- ✓ Comprehensive Overview
- ✓ Table format
- ✓ Analysis by indicator
- → available for download at PPRI website by end of October 2007





# Contact

### Overall coordination / Indicators / Benchmarking / Dissemination

GÖG/ÖBIG – Austrian Health Institute Claudia Habl, Sabine Vogler, Ingrid Rosian, Christine Leopold (<u>lastname@oebig.at</u>; <u>ppri@oebig.at</u>) Tel: +43 1 51561-0

### **Needs Assessment / Pharma Profiles**

WHO Regional Office for Europe Kees de Joncheere, Trine Lyager Thompsen (<u>TLT@euro.who.int</u>; <u>CJO@euro.who.int</u>; <u>ppri@oebig.at</u>)

Tel: +45 39 171 432

Website: http://ppri.oebig.at